Journal

TORTUS Health needs evidence for information gathering, clinician review and the whole care service, not only the quality of generated notes.

Compare TORTUS Health and Heidi II through the patient relationship, clinical work, business model, regional access and responsibility for follow-through.

Assess AI-led virtual care through complete episode costs, clinician review, repeat contacts and patient expenses rather than the price of an AI conversation.

Routine healthcare requests can hide relevant clinical context, making transaction completion an incomplete test of agent performance.

A dated healthcare-agent tracker separating actual functions, regional access, previews, pilots and clinician approval from broad company announcements.

TORTUS Health introduces a patient-facing care proposition alongside NHS documentation, creating new operational demands without proving an NHS exit.

Compare clinician-reviewed virtual care, bounded acne prescribing and medication renewal by clinical task, oversight, eligibility and authority.

Compare TORTUS Health and TORTUS AI by intended user, workflow, geography, clinician involvement and the evidence that applies to each product.

Understand TORTUS Health's California-first virtual care proposition, clinician approval, staged access and the evidence still needed to assess the service.

Integrated AI care could improve follow-through, but payment incentives, complete episode costs and appropriate non-treatment outcomes need explicit scrutiny.

Nolla Health illustrates why the breadth of an AI care service and the autonomy of its prescribing decisions must be assessed separately.

Revisit General Catalyst's 2025 investment in Nolla Health and the business questions raised by its October 2026 AI acne-prescribing pilot.